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We demonstrated previously that the pseudokinase domain of JAK2 in fact possesses low catalytic activity, phosphorylating two negative regulatory sites in JAK2 (ref. 11), and we subsequently determined its crystal structure 12 . Numerous crystal structures of the tyrosine-kinase domain of JAK2 have been determined, but attempts to crystallize the tandem kinase domains of JAK2 have been unsuccessful so far. Here, we used long-time-scale molecular dynamics (MD) simulations, guided by biochemical knowledge of the system, to generate a structural model for the autoinhibitory interaction between the pseudokinase and kinase domains of human JAK2. Our model, which is supported by extensive mutagenesis data, can provide a rationale for nearly all of the gain-offunction disease mutations in JAK2. results generation of the JaK2 JH2-JH1 model To generate a structural model for the autoinhibitory interaction between the JAK2 pseudokinase domain (JAK homology-2, JH2) and tyrosinekinase domain (JH1) that could then be tested experimentally, we simulated the JH2-JH1 interaction without any presumption of the binding pose, in a manner similar to that for small molecule-protein binding 13 . We placed atomic structures of JH2 and JH1 in an arbitrary untethered and noncontacting pose within a box of explicit solvent molecules (Fig. 1,  state 1 ). From this starting pose, we ran 14 independent MD simulations of 3 µs each, each of which resulted in a JH2-JH1 configuration in which Janus kinases (JAKs 1-3 and TYK2) are protein tyrosine kinases that mediate cytokine signaling 1 . JAKs possess an N-terminal band 4.1, ezrin, radixin, moesin (FERM) domain and a Src homology-2 (SH2)-like domain, which are responsible for cytokine-receptor association 2 , and tandem protein-kinase domains: a pseudokinase domain and a tyrosine-kinase domain. JAKs are activated through cytokineinduced trans-phosphorylation, either as heterodimeric receptor-JAK complexes (all JAKs) or as homodimeric receptor-JAK2 complexes. Signaling through JAK-signal transducer and activator of transcription (STAT) pathways are essential for cell growth, differentiation, proliferation and survival, particularly in hematopoiesis, as well as for the initial events in innate and adaptive immunity 1 .
Mutations in JAK genes are causally linked to human MPNs, which are clonal proliferative disorders affecting different myeloid lineages 3 . The more common MPNs-polycythemia vera, essential thrombocythemia and primary myelofibrosis-are caused in most cases by mutations in the pseudokinase domain of JAK2 (refs. 3,4) . Mutations in the pseudokinase domain of JAK genes have also been linked to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia 4 . All of these pseudokinase-domain mutations result in constitutive activity of the tyrosine-kinase domain. V617F in the JAK2 pseudokinase domain is the most commonly identified mutation in MPNs [5] [6] [7] ; it is responsible for ~95% of cases of polycythemia vera and also been implicated in non-small cell lung cancer 8 . These clinical data, as well as biochemical data 9, 10 , implicate the pseudokinase domain as a negative regulatory domain necessary to maintain low basal JAK2 activity, Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase Janus kinase-2 (JaK2) mediates signaling by various cytokines, including erythropoietin and growth hormone. JaK2 possesses tandem pseudokinase and tyrosine-kinase domains. mutations in the pseudokinase domain are causally linked to myeloproliferative neoplasms (mPns) in humans. the structure of the JaK2 tandem kinase domains is unknown, and therefore the molecular bases for pseudokinase-mediated autoinhibition and pathogenic activation remain obscure. using molecular dynamics simulations of protein-protein docking, we produced a structural model for the autoinhibitory interaction between the JaK2 pseudokinase and kinase domains. a striking feature of our model, which is supported by mutagenesis experiments, is that nearly all of the disease mutations map to the domain interface. the simulations indicate that the kinase domain is stabilized in an inactive state by the pseudokinase domain, and they offer a molecular rationale for the hyperactivity of V617F, the predominant JaK2 mPn mutation. a r t i c l e s 
Description of the model
The most striking feature of our model for the autoinhibitory interaction between JH2 and JH1 of JAK2 is the positioning of nearly all of the mapped disease mutations 4 , and of other gain-of-function mutations 19 , in or proximal to the interdomain interface ( Fig. 2a and Supplementary Fig. 1c) . The JH2-JH1 interface can be subdivided into four regions: region 1, the β2-β3 loop of JH2 and the β-sheet in the N lobe of JH1 (Fig. 2b) ; region 2, β7-β8 of JH2 and the β2-β3 loop of JH1 (Fig. 2c) ; region 3, the end of αC in JH2 and the kinase hinge region of JH1 (Fig. 2d) ; and region 4, the SH2-JH2 linker, αC of JH2 and α-helix D (αD) of JH1 (Fig. 2e) . Although residues in the JH2-JH1 linker also interacted with JH2 and JH1 during the simulations, these interactions were generally less stable and will not be enumerated.
In region 1 (Fig. 2b) , phosphotyrosine (pTyr) 570 in the β2-β3 loop of JH2 inserted into the pocket formed by the curved β sheet in the N lobe of JH1 and made salt bridges with Lys883 (β3), Lys926 (β5) and Arg922 (β4-β5 loop). In region 2 (Fig. 2c) , the simulations showed a stable salt bridge between two residues, Arg683 (β7) in JH2 and Asp873 (β2-β3 loop) in JH1; mutation of each residue (R683S or D873N) has been linked to ALL 4 . Thr875, also in the β2-β3 loop, is the site of another disease mutation (T875N; acute megakaryoblastic leukemia 4 ). In addition to Arg683, Lys607 (K607N; acute myeloid leukemia 4 ) (αC-β4 loop) also the two domains were in contact (Fig. 1, state 2) . We did not include the 29-residue JH2-JH1 linker at this early stage of the simulations because initial simulations with the linker resulted in entanglement of JH1 or JH2 with the linker, and this entanglement could not be easily resolved in the relatively short (3-µs) simulation time. We knew from mutagenesis data in the literature, and from the lack of sequence conservation, that the JH2-JH1 linker was not a critical component of autoinhibition. Therefore, for computational efficiency, we chose to omit the linker initially and focus on direct JH2-JH1 interactions.
Visual inspection revealed a large variation in JH2-JH1 poses from these 14 simulations (Fig. 1, state 2) . One of the 14 poses (pose 2) possessed two key characteristics: the JH2-JH1 interface included α-helix C (αC) in JH2, which we and others had identified previously as a structural element in the regulation of JH1 by JH2 (refs. 12,14) , and the C terminus of JH2 and the N terminus of JH1 could readily be connected by the JH2-JH1 linker. For these reasons, we chose to pursue pose 2. We also subjected these 14 simulations to two empirical protein-docking scoring functions (EMPIRE 15 and OSCAR 16 ), and pose 2 scored better than the others (Supplementary Fig. 1a) . However, because our final model differs substantially from this initial pose ( Supplementary Fig. 1b and as described below), and the interaction energy of the linker is likely to be non-negligible, the docking scores were not of fundamental consequence.
In the next phase of modeling, we added the JH2-JH1 linker to JH2-JH1 pose 2 ( Fig. 1, state 3 ) and performed four simulations of the resulting system (residues 536-1131). In these simulations, the addition of the linker caused major movements of JH1 relative to JH2. One simulation of 1.7 µs (Fig. 1, states 3 and 4) resulted in an r.m.s. deviation of ~9 Å for JH2 and JH1 (Cα atoms) relative to the starting position (state 3). The resultant JH2-JH1 pose from this simulation was appealing because additional interdomain contacts were established, which were between the 'backside' (β7-β8 loop) of JH2 and the N lobe of JH1 (β2-β3 loop) (described in detail below). In addition, a negative regulatory phosphorylation site, Tyr570 (refs. 11,17,18) , in the β2-β3 loop of JH2, which was phosphorylated from the outset of the simulations, settled into a positively charged pocket in the N lobe of JH1 (described in detail below).
Because of the negative regulatory role of the SH2-JH2 linker 19 -in particular Ser523 (refs. 20,21) , a JH2 phosphorylation site 11 -we then added residues 520-535 to the model with Ser523 phosphorylated (Fig. 1 , state 5). We simulated JAK2 residues 520-1131, which encompassed the SH2-JH2 linker (C-terminal half), JH2 and JH1, for 40 µs. After several microseconds, a defined interaction between JH2, JH1 and the SH2-JH2 linker was established, which we term the JH2-JH1 autoinhibitory pose ( a r t i c l e s npg expectation was that the single point mutants would be partially activated, because of destabilization of the JH2-JH1 interaction, but that the activation state of the double mutant would be suppressed, owing to formation of the 'reverse' salt bridge and restoration of the autoinhibited state. Indeed, both Y570R and K883E were activated by a factor of ~4 relative to wild-type JAK2, and, strikingly, the activation state of the double mutant was similar to that of wild type, i.e., was suppressed ( Fig. 3a and Supplementary Fig. 2a ), consistently with reverse salt-bridge formation. In region 2 ( Fig. 2c) , we probed the interaction between Arg683 (JH2) and Asp873 (JH1) (both ALL mutations). We first generated the charge-reversal mutants R683E, D873R and R683E D873R. Although R683E was activated by a factor of ~20 ( Fig. 3b and Supplementary  Fig. 2a) , D873R was not activated, and testing of D873R in the context of JH1 alone revealed that this mutation (and also D873K) compromised JH1 activation-loop phosphorylation ( Supplementary  Fig. 2b ), even though Asp873 is at a considerable distance from the JH1 active site (Fig. 2a) . We then tested the actual disease mutant, D873N, and the double mutant R683E D873N. D873N was activated by a factor of ~17, whereas activation of the double mutant, in comparison to that of the two single mutants, was substantially reduced (Fig. 3b and  Supplementary Fig. 2a) . These data suggest a direct interaction between these two residues. It is conceivable that Asn873 interacts more favorably with Glu683 (in R683E D873N) than with Arg683 (in D873N), given that asparagine-glutamate interactions have been found empirically to be energetically more favorable than asparagine-arginine interactions 24 . Consistently with this interpretation, in simulations, the single mutations (R683E and D873N) partially destabilized the JH2-JH1 interaction, whereas the double mutation (R683E D873N) restored wild-type stability (Supplementary Fig. 3a) . Further support of a direct interaction of Arg683 with JH1 (Asp873) comes from a crystal structure of JAK2 JH2 R683S (data not shown), which shows that this disease mutation does not affect the structure (global or local) of JH2. Thus, it is unlikely that substitution of Arg683 destabilizes the JH2-JH1 interaction through structural perturbation of JH2.
In region 3 ( Fig. 2d) , we took advantage of a disease (ALL) mutation, P933R, which substitutes a positively charged residue in the hinge region between the JH1 kinase lobes. Residue 603 (Lys603 in humans and Gln603 in mice) in JH2 is opposite Pro933 in our JH2-JH1 model, so we tested whether substitution of a negatively charged residue at 603 could suppress the hyperactivation of P933R by creating a favorable charge interaction across the interface. For this purpose, we generated mutants (in mouse JAK2) Q603E, P933R and Q603E P933R. Q603E had activity comparable to that of wild-type JAK2, as expected given that this residue is not conserved in mammalian species; P933R was activated by a factor of ~13; and Q603E, as predicted from the model, suppressed the activation of P933R (Q603E P933R) ( Fig. 3c and Supplementary  Fig. 2a) . Because in this case only one of the two single mutants in the formed a salt bridge with Asp873 during the simulation. In region 3 (Fig. 2e) , Pro933 in the JH1 hinge region, which links the N and C lobes, formed a small hydrophobic cluster with Met600 and Leu604 (αC and just after) in JH2. Val878 (β3) and Tyr931 (hinge) in JH1 also contribute to this hydrophobic cluster. P933R was mapped as an activating mutation in ALL 22 . Finally, in region 4 (Fig. 2e) , the SH2-JH2 linker made contacts with αC of JH2 and αD of JH1. In addition to SH2-JH2 linker-mediated contacts between the domains, stable salt bridges were formed between Glu592 (αC, JH2) and Arg947 (αD-αE loop, JH1) and between Arg588 (αC, JH2) and pSer523 (SH2-JH2 linker). Arg947 also interacted with pSer523 during the simulation. Notably, the mutation R588A was shown previously to be partially activating 23 .
experimental validation of the model To provide experimental validation for the autoinhibitory model of JAK2 JH2-JH1 derived from the MD simulations, we explored charge-reversal mutations in each of the four regions of the JH2-JH1 interface. In region 1 (Fig. 2b) , we generated the individual point mutations Y570R (charge reversal of pTyr570; JH2) and K883E (JH1) and the double mutation Y570R K883E in full-length JAK2 and transfected them into COS7 cells. We measured JH1 activation-loop phosphorylation (pTyr1007-pTyr1008)-the standard readout of JAK2 activation-and downstream STAT1 phosphorylation and STAT3-mediated gene transcription. The 
a r t i c l e s npg
Thus, on the basis of the JH2-JH1 model, we predicted and confirmed experimentally three new activating mutations in JAK2-two in JH1 (K883E and R947E) and one in JH2 (Y570R)-each of which could be suppressed with a mutation across the JH2-JH1 interface. We also predicted and confirmed that a mutation in JH2 (Q603E) could suppress a disease mutation in JH1 (P933R).
autoinhibitory mechanism
In our model for the interaction between JAK2 JH2 and JH1, the activation loop of JH1 is unencumbered, and the active site is accessible to substrates (Fig. 2a) . However, our simulations suggest that the interaction with JH2 leads to a more extended configuration of the JH1 lobes (Supplementary Fig. 4a) , which is reminiscent of the effect of the SH2 and SH3 domains on the kinase domain of Abl in the autoinhibited putative JH2-JH1 interface was activated, we confirmed that Q603E (JH2) does not cause impairment of JAK2 (for example, loss of receptor engagement) by verifying that Q603E and Q603E P933R could be activated by erythropoietin (Epo) in γ2A cells cotransfected with Epo receptor (Supplementary Fig. 2c) .
Finally, in region 4 ( Fig. 2e) , we created charge-reversal mutants E592R (JH2), R947E (JH1) and E592R R947E. R947E was activated by a factor of ~4 ( Fig. 3d and Supplementary Fig. 2a) . E592R, however, was not activated; this was unexpected because mutation to alanine (E592A) was shown previously to be partially activating 23 . MD simulations of E592R provided a rationale for the experimental result: Arg592 can form a salt bridge with pSer523, along with Arg947 ( Supplementary  Fig. 3b) , to stabilize the autoinhibitory state. Importantly, the double mutant (E592R R947E) was not activated (Fig. 3d and Supplementary  Fig. 2a) , i.e., E592R suppressed the hyperactivation of R947E, consistently with formation of the reverse salt bridge (Arg592-Glu947), which indeed formed and was stable in the simulation of E592R R947E ( Supplementary  Fig. 3b ). As for Q603E above, because E592R (JH2) was not activated on its own (yet suppressed R947E), we confirmed that this mutation does not impair JAK2 by coexpressing E592R and E592R R947E with Epo receptor and stimulating with Epo (Supplementary Fig. 2c ). (β3) and Glu898 (αC). The distance is plotted as a function of simulation time for simulations of JAK2 JH2-JH1 or JH1 alone (with JH1 activation loop unphosphorylated for both). To simplify the salt-bridge presentation (to account for both Oε1 and Oε2 of Glu898), the actual distance displayed is between Nζ of Lys882 and Cδ of Glu898, and the gray region indicates the saltbridging distance range. (b) DFG-in and DFG-out states of the JH1 activation loop. Left, active state of JH1 (PDB 3KRR 34 ), in which the Lys882-Glu898 salt bridge is formed, and Asp994 and Phe995 of the DFG motif in the activation loop adopt the DFG-in (active) conformation. Right, simulation of JH2-JH1, during which the Lys882-Glu898 salt bridge is disrupted, and the DFG motif more readily adopts a DFG-out (inactive) conformation (shown is a snapshot taken after 12 µs of the simulation). Coloring is the same as in Figure 1 .
a r t i c l e s npg in JAK2) and R724S (R683S in JAK2). Indeed, a 12-µs simulation of JH2 and JH1 of JAK1 (whose interdomain linker is 14 residues shorter than in JAK2) showed that the key interface interactions are conserved, with most of the known activating mutations in JAK1 clustered in the interface (Supplementary Fig. 5a ). During the simulation, salt bridges were established between Arg724 in JH2 (Arg683 in JAK2) and Asp899 and Glu897 (Asp873 and Leu871 in JAK2) in the β2-β3 loop of JH1, despite Arg724 being located >9 Å from these acidic residues at the start of the simulation. Although the β2-β3 loop in JAK1 JH2 does not contain a known phosphorylation site, in the simulation Glu609 in the loop interacted with Lys888 (β2) and Lys911 (β3-αC loop) in the N lobe of JH1 (Supplementary Fig. 5a ), similarly to the interaction in JAK2 between pTyr570 and Lys883 (β3) and Lys926 (β5) (Fig. 2b) . (Structural coordinates for the JAK1 JH2-JH1 model (a representative snapshot from the simulation) are included in Supplementary Data Set 2).
Discussion
In this study, we used long-time-scale MD simulations to generate a molecular model for the autoinhibitory interaction between the pseudokinase domain (JH2) and tyrosine-kinase domain (JH1) of JAK2. Our goal in performing the MD simulations was to see whether we could generate a plausible model for the JH2-JH1 interaction that we could then test experimentally. Although the particular MD simulation approach that we took, which entailed decisions on the basis of biochemical and structural knowledge of JAK2, is far from a 'turnkey' method for ab initio modeling of protein-protein interactions, the current work highlights the potential of MD simulations as a powerful tool for structural elucidation of such interactions. In our model, nearly all of the activating disease mutations are present in the JH2-JH1 interface, thus providing a molecular rationale for oncogenic activation through mutation: destabilization of the JH2-JH1 interaction results in more facile JH1 trans-phosphorylation (Fig. 5) . Although the MD simulations of JH2-JH1 can provide insights into specific oncogenic mutations, such as D873N or V617F ( Supplementary  Figs. 3a and 4c-e) , they are not able to predict, for example, the relative degree to which a mutation in JAK2 will be activating in cells. Moreover, to know whether destabilization of the SH2-JH2 linker is the sole mechanism by which V617F is activated will require additional structural and mechanistic studies.
Our JAK2 JH2-JH1 model is fundamentally different from models proposed previously 23, 29, 30 , in which only V617F among the many MPN mutations is present in the respective JH2-JH1 interfaces (Supplementary Fig. 5b) . In the prevailing model in the field 29 , JH2 state 25 . Because substantial lobe movements occur in protein kinases during the phosphoryl-transfer process 26 , and the JH2 interaction with JH1 in the model involves both lobes of JH1, this interaction should suppress JH1 catalytic activity. In addition, the simulations indicate that binding of JH2 to JH1 destabilizes the catalytically important β3-αC (Lys882-Glu898) salt bridge in JH1 (Fig. 4a) and might facilitate the so-called 'DFG flip' in the activation loop 25, 27 . Indeed, the DFG-out, catalytically inactive state was reached in the simulation of JH2-JH1, starting from the DFG-in (active) state (Fig. 4b) . Taken together, the simulations suggest that the interaction of JH2 with JH1 stabilizes an inactive state of JH1 (Fig. 5) .
Although phosphorylation of Ser523 and Tyr570 is posited to fortify the JH2-JH1 autoinhibitory interaction (Fig. 2b,e) , phosphorylation of the JH1 activation loop (Tyr1007-Tyr1008), which stabilizes the active state, conversely might destabilize the JH2-JH1 interaction. This concept is supported by MD simulations of JH2-JH1, in which phosphorylation of the JH1 activation loop leads to a higher JH1 r.m.s. deviation than when the activation loop is unphosphorylated (Supplementary Fig. 4b ). Presumably, a high degree of conformational freedom for JH1 is necessary for phosphorylation of other sites in JAKs (for example, Tyr813 in JAK2), the cytokine receptor and recruited STAT proteins. mechanism of V617F activation Val617, the site of the predominant MPN-causing mutation, V617F [5] [6] [7] , is not situated directly in the JH2-JH1 interface but rather is proximal to the SH2-JH2 linker (Fig. 2e) , which was shown previously to be important for maintenance of the JAK2 basal state 19 . To gain insights as to how this mutation results in constitutive activation of JAK2, we simulated V617F JH2-JH1. Analysis of the simulation trajectories suggests that the bulky phenylalanine at residue 617 destabilizes the position of the SH2-JH2 linker between JH2 and JH1 (Supplementary Fig. 4c ), which in turn results in increased conformational heterogeneity of JH1 relative to JH2 (Supplementary Fig. 4d) . Accordingly, the catalytically active conformation of αC in JH1 (β3-αC salt bridge; Fig. 4b ) is more stable in V617F than in wild-type JAK2 (Supplementary Fig. 4e) . A mutation in αC of JH2, F595A, has been shown previously to suppress V617F 14, 28 , and in a simulation of the double mutant V617F F595A, the SH2-JH2 linker position is again stable between JH2 and JH1 (Supplementary Fig. 4c ).
applicability to other JaKs The proposed autoinhibitory interaction between JH2 and JH1 of JAK2 should be applicable to the other JAKs as well, in particular JAK1, which shares several disease mutations with JAK2, including V658F (V617F and is transiently active. The N and C lobes of JH2 and JH1 are labeled. Phosphorylated Ser523 and Tyr570 stabilize the autoinhibited state by binding to positively charged residues (blue patches) in JH1 and JH2 (also Fig. 2b,e) . Ser523 is constitutively phosphorylated 20 (magenta sphere), whereas Tyr570 is substoichiometrically phosphorylated in the basal state (mixed white-and-magenta sphere). Tyr570 phosphorylation increases upon JAK2 activation 18 , probably serving as a negative feedback mechanism (to promote the autoinhibited state). In the basal state (no cytokine), the two JAK2 molecules (only one JH2-JH1 shown) associated with a cytokine-receptor dimer are maintained in positions that limit trans-phosphorylation of the JH1 activation loop (Tyr1007-Tyr1008). Right, cytokine binding and receptor rearrangement juxtapose the two JAK2 molecules to facilitate JH1 trans-phosphorylation of the activation loop, which in turn activates JAK2 (JH1, green). Activating mutations such as D873N, R683S or V617F destabilize the autoinhibited state, permitting trans-phosphorylation of the JH1 activation loop in the basal state.
a r t i c l e s npg sterically prevents the JH1 activation loop from adopting an active conformation, and the SH2-JH2 linker has no role in the JH2-JH1 interaction. In our model, JH2 binds to the backside of JH1, stabilizing an inactive conformation of JH1, and the SH2-JH2 linker serves as a bridging element between JH2 and JH1. The conformation of the SH2-JH2 linker in our model differs from that in the crystal structure of JAK1 JH2 (ref. 31) , but this may be because of the absence of JH1 in the crystallized protein.
After our study was completed, a crystal structure of TYK2 JH2-JH1 was reported 32 . Our simulations-based models for JAK2 and JAK1 JH2-JH1 are in striking accord with the TYK2 structure. All of the key JH2-JH1 interactions in the JAK2 and JAK1 models are present in the TYK2 structure, in particular, those between β7-β8 in JH2 and the β2-β3 loop in JH1 (Fig. 2c) and between the end of αC in JH2 and the hinge region in JH1 (Fig. 2d) . On average, the JAK2 model is 3.7 Å (r.m.s. deviation for Cα atoms in JH2-JH1) away from the TYK2 crystal structure (PDB 4OLI 32 ) over the 40-µs simulation, and the JAK1 model is 3.3 Å away over the 12-µs simulation.
The JH2-mediated autoinhibitory mechanism described above would serve to limit trans-phosphorylation of JAK molecules associated either with heterodimeric receptors juxtaposed through ligand binding or with preformed homodimeric receptors (for example, the Epo receptor) reconfigured by ligand binding. For JAK2, which is the only JAK to associate with preformed homodimeric receptors, the phosphorylation of Ser523 (refs. 11,20,21) and Tyr570 (refs. 11, 17, 18) , which is unique to JAK2, provides an additional mechanism of JH2-JH1 stabilization (Figs. 2b,e and 5) .
Finally, there is considerable interest in developing V617F-specific inhibitors of JAK2 for treatment of MPNs, to minimize the toxicity associated with concomitant inhibition of wild-type JAK2 (ref. 33) . By providing an understanding of how JH2 and JH1 interact in the basal state, our model should be valuable for the screening and design of small molecules that could fortify this interaction and potentially serve as new therapeutic inhibitors of V617F or other oncogenic JAK2 mutants. metHoDs Methods and any associated references are available in the online version of the paper. 
